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IMPORTANCE End-of-life decisions occur daily in intensive care units (ICUs) around the world,
and these practices could change over time.
OBJECTIVE To determine the changes in end-of-life practices in European ICUs after 16 years.
DESIGN, SETTING, AND PARTICIPANTS Ethicus-2 was a prospective observational study of 22
European ICUs previously included in the Ethicus-1 study (1999-2000). During a self-selected
continuous 6-month period at each ICU, consecutive patients who died or had any limitation
of life-sustaining therapy from September 2015 until October 2016 were included. Patients
were followed up until death or until 2 months after the first treatment limitation decision.
EXPOSURES Comparison between the 1999-2000 cohort vs 2015-2016 cohort.
MAIN OUTCOMES ANDMEASURES End-of-life outcomeswere classified into 5mutually
exclusive categories (withholding of life-prolonging therapy, withdrawing of life-prolonging
therapy, active shortening of the dying process, failed cardiopulmonary resuscitation [CPR],
brain death). The primary outcomewas whether patients received any treatment limitations
(withholding or withdrawing of life-prolonging therapy or shortening of the dying process).
Outcomes were determined by senior intensivists.
RESULTS Of 13 625 patients admitted to participating ICUs during the 2015-2016 study
period, 1785 (13.1%) died or had limitations of life-prolonging therapies and were included in
the study. Compared with patients included in the 1999-2000 cohort (n = 2807), patients in
the 2015-2016 cohort were significantly older (median age, 70 years [IQR, 59-79] vs 67 years
[IQR, 54-75]; P < .001) and the proportion of female patients was similar (39.6% vs 38.7%;
P = .58). Significantly more treatment limitations occurred in the 2015-2016 cohort
compared with the 1999-2000 cohort (1601 [89.7%] vs 1918 [68.3%]; difference, 21.4%
[95% CI, 19.2%-23.6%]; P < .001).
Limitation
2015-2016,
No. (%)
1999-2000,
No. (%) Difference, % (95% CI)
P
Value
Withholding of life-prolonging therapy 892 (50) 1143 (40.7) 9.3 (6.4 to 12.3) <.001
Withdrawing of life-prolonging therapy 692 (38.8) 695 (24.8) 14.0 (11.2 to 16.8) <.001
Failed CPR 110 (6.2) 628 (22.4) −16.2 (−18.1 to −14.3) <.001
Brain death 74 (4.1) 261 (9.3) −5.2 (−6.6 to −3.8) <.001
Active shortening of the dying process 17 (1.0) 80 (2.9) −1.9 (−2.7 to −1.1) <.001
CONCLUSIONS AND RELEVANCE Amongpatientswhohad treatment limitations or died in 22
European ICUs in 2015-2016, comparedwith data reported from the same ICUs in 1999-2000,
limitations in life-prolonging therapies occurred significantlymore frequently and deathwithout
limitations in life-prolonging therapies occurred significantly less frequently. These findings
suggest a shift in end-of-life practices in European ICUs, but the study is limited in that it
excluded patientswho survived ICUhospitalizationwithout treatment limitations.
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D eath in intensive care units (ICUs) frequently occursafter a decision to limit life-sustaining interventions.Despite international consensus formanyethical prin-
ciples underlying ICU end-of-life care,1 there are consider-
able variations in actual practice within and between coun-
tries and regions.2 For example, in the Ethicus-1 study
conducted from January 1999until July 2000 in 37 European
ICUs, the frequency of withholding life-prolonging therapies
ranged from 16% to 70%, withdrawing life-prolonging thera-
pies from 5% to 69%, active shortening of the dying process
from 0% to 19%, and failed cardiopulmonary resuscitation
(CPR) from 5% to 48%.3
Over the past decade, there have been changes in
European attitudes,1,4 laws,5 recommendations6,7 and guide-
lines8,9 regarding end-of-life practices. Although paternalism
persists among some European caregivers,4 more shared
decision making has been advocated.10 Recently, European
public support for euthanasia and physician-assisted sui-
cide has increased, resulting in more deaths from these
practices.11 The actual extent of end-of-life practice changes
across European ICUs remains unknown. The present
Ethicus-2 study was designed to assess whether there has
been a change in end-of-life practices in European ICUs from
1999-2000 to 2015-2016.
Methods
Centers
All 37 centers that initially participated in the Ethicus-1 study
(1999-2000cohort)3were invitedtoparticipate in theEthicus-2
study (2015-2016 cohort). Several ICUsno longer existed, and
some others declined participation, resulting in the inclusion
of 22 of the original 37 ICUs in the present study. The contrib-
uting regions and countries included Northern Europe
(Denmark, Ireland,TheNetherlands,andtheUnitedKingdom),
Central Europe (Belgium, Czech Republic, Germany, and
Switzerland), and Southern Europe (Greece, Israel, Italy,
Portugal, Spain, and Turkey). These ICUs represent 14 of the
original 17 countries. Data from ICUs that participated in
the 1999-2000 study but not the 2015-2016 study (ICUs
inAustria,Finland,andSweden)werenot included in thiscom-
parison study. Institutional ethics committee approval, with
a waiver of informed consent, was obtained from each par-
ticipating center. Countries and centers were coded anony-
mously and study patients were numbered consecutively to
ensure confidentiality and to enable clinicians to report prac-
tices without risk of legal liability.
Patients
This study used the same study population definitions,
ethical and legal considerations, and data collection methods
as were used in the 1999-2000-cohort.3 Consecutive adult
patients admitted to participating ICUs who died or had
any limitation of life-saving interventions over a 6-month
period were selected by each ICU between September 1, 2015,
and September 30, 2016, and were prospectively included
in the study. Patients were followed up until discharge from
the ICU, death, or 2 months from the first decision to limit
life-prolonging therapies.
Outcomes
End-of-life outcomes were classified into 5 mutually exclu-
sive categories: withholding of life-prolonging therapy, with-
drawing of life-prolonging therapy, active shortening of
the dying process, failed CPR, and brain death. The primary
outcome was whether patients received any limitations in
life-prolonging therapy (withholding or withdrawing of life-
prolonging therapy, or shortening of the dying process).
Study Definitions for End-of-Life Categories
• Withholding treatment—a decision wasmade not to start or
increase a life-sustaining intervention, such as not to per-
form CPR if a patient had a cardiac arrest.
• Withdrawing treatment—adecisionwasmade toactively stop
a life-sustaining intervention presently being given, such as
stopping a norepinephrine infusion being given for shock.
• Active shortening of the dying process—a circumstance
in which someone performed an act with the specific in-
tent of shortening the dying process; these acts did not
include withholding or withdrawing although withholding
or withdrawing could occur prior to active shortening of the
dying process.
• Failed CPR—death despite ventilation and cardiac massage.
• Braindeath—documented cessationof cerebral function and
meeting criteria for brain death.
A hierarchical categorization was used for the most active
limitation if more than one occurred (active shortening of
the dying process > withdrawing > withholding). Secondary
outcomes included hospital survival or death; specific limi-
tations of therapies including failed CPR, intubation, venti-
lation, vasopressors, and renal replacement therapy; ICU
length of stay; time until initiating the first life-sustaining
limitation; time after initiating the first life-sustaining limi-
tation until death; time until withholding or withdrawing
life-sustaining therapies or active shortening of the dying
Key Points
Question Have end-of-life practices in European intensive care
units (ICUs) changed from 1999-2000 to 2015-2016?
Findings In this prospective observational study of 1785 patients
who had limitations in life-prolonging therapies or died in 22
European ICUs in 2015-2016, compared with data previously
reported from the same ICUs in 1999-2000 (2807 patients),
treatment limitations (withholding or withdrawing life-sustaining
treatment or active shortening of the dying process) occurred
significantly more frequently (89.7% vs 68.3%), whereas death
without any limitations in life-prolonging therapies occurred
significantly less frequently (10.3% vs 31.7%).
Meaning These findings suggest that end-of-life care practices in
European ICUs changed from 1999-2000 to 2015-2016 with more
limitations in life-prolonging therapies and fewer deaths without
treatment limitations.
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process; patient and institutional characteristics and prob-
abilities of death. Post hoc outcomes included ICU charac-
teristics and ethical practices (see following section for fur-
ther explanation).
Study Procedures and Data Collection
No interventions or treatmentswere given,withheld, orwith-
drawn from patients for study purposes. At each institution,
the senior intensivist responsible for end-of-life decisionsde-
terminedwhichend-of-life practiceoccurredandwas respon-
sible for completing the study data form including outcomes.
Similar data forms to those used for the 1999-2000 cohort
were used, and data were entered using a dedicated and se-
cured website. Patient data collected included sex, age, reli-
gious affiliation, ICU admission diagnosis, chronic disorders,
end-of-lifecategory,specifictherapylimitations,datesandtimes
ofhospital and ICUadmission,deathordischarge, decisions to
limit interventions, and hospital survival or mortality.
Additional procedures to improve validity and consis-
tency included adherence to the study protocol (Supple-
ment 1), following specific instructions for study perfor-
mance anddata formcompletion, providing concurrent audit
and feedback, having immediate answers to frequently asked
questions, andhavingaquality assuranceprogramthat evalu-
ated 5% of all patients (crosschecking accuracy of data entry
was 8841/9249 [96%]).
To evaluate changes in the ICUs from 1999-2000 to 2015-
2016, investigators from the participating centers provided
data on ICU variables for both time periods including ICU
type, ICU and hospital number of beds, ICUmean admissions
per month, and ICU physician and nursing staffing. Yearly
ICU mortality was calculated from each ICU’s total admission
number and mortality.
Inanattempt tounderstandstudyresults in relationtopos-
sible changes inethical practicebetween1999-2000and2015-
2016, investigators were surveyed in 2019 to retrospectively
provide data regarding 12 variables that represent various as-
pects of ethical practice. Variable selectionwas based on a re-
cent worldwide consensus1 and on current, evidence-based
guidelines and policy statements.8-10,12 Variable data were
collected in a binary (yes/no) form andwere based on the fol-
lowing items: (1) routine familymeetings1,10,12; (2) daily delib-
eration for the appropriate level of care1; (3) end-of-life dis-
cussionsduringmeetings1; (4)written triggers for limitations9;
(5) written end-of-life guidelines5; (6) written protocols9;
(7) palliative care consultations10; (8) ethics consultations10;
(9) staff taking communications courses1,10,12; (10) staff tak-
ing bioethics courses1,8,10,12; (11) each country’s end-of-life
guidelines1; and (12) eachcountry’s legislation.1 For eachof the
12 ethical practice–related variables for the 2 study periods,
a positive answer was graded as 1 and a negative answer as 0.
The sumwas operationalized as an ICU-specific ethical prac-
tice score with a range of 0 to 12 points. This score was de-
rived for the purposes of this study.
Statistical Analyses
The number of ICU admissions per month (turnover) catego-
rized institutions as small (≤30), intermediate (31-60), or large
(≥61). Institutions were also dichotomized into academic vs
nonacademiccenters.Foreachpatient, themainoutcomevari-
ablewas the end-of-life category. Continuous variables show-
ing a symmetric and close to normal distribution are ex-
pressed as mean (SD) and compared using the t test.
Percentages were compared using the χ2 or Fisher exact test.
Numeric asymmetric variables are presented asmedian inter-
quartile range (IQR) and compared with the nonparametric
Mann-Whitney test (independent samples) or the Wilcoxon
signed rank test (paired samples). For paired samples, the pri-
marysamplingunitwascentersparticipating in1999-2000and
in2015-2016.Probabilitiesofdeathwithin24,48, and72hours
of decisions for withholding andwithdrawing life-sustaining
treatmentsandactiveshorteningof thedyingprocesswereper-
formed for both study periods.
Pairwise exclusionwas themethodused formissingdata.
A case that had a missing value for any variable was omitted
from the analysis for each table or analysis separately. Be-
causeof thepotential for type 1 error due tomultiple compari-
sons, findings for analyses of secondary end points should be
interpretedasexploratory.Anadditional, exploratory,posthoc,
multivariable, logistic regressionanalysis isdetailed inSupple-
ment 2. Statistical analyses were performed using IBM SPSS
version24.A testwas considered significant if thePvaluewas
less than .05. P values were 2-sided.
Results
At the 22 centers participating in this study, 13 625 patients
(range, 82-1440 patients per center) were admitted over 5.9
months (range, 1-6 months) in 2015-2016. Of these patients,
1785 (13.1%) died or had limitations of life-sustaining treat-
ments and constituted the 2015-2016 study population. In
1999-2000, these 22 centers admitted 22081 patients (range,
143-3118 patients per center) over 13.7 months (range, 1-18
months), and 2807 (12.7%) died or had limitations of life-
sustaining treatments. Patient characteristics in the 2015-
2016and 1999-2000cohorts arepresented inTable 1. Thepro-
portion of patients enrolled in the cohort because limitations
were placed on life-sustaining therapy (withholding or with-
drawing life-sustaining treatment or active shortening of the
dying process) was significantly higher in 2015-2016 (1601
[89.7%]) than in 1999-2000 (1918 [68.3%]; difference, 21.4%
[95% CI, 19.2% to 23.6%]; P < .001), while patients who were
enrolled because of death occurring without any limitations
in life-prolonging therapies (failed CPR and brain death) was
significantly less frequent in 2015-2016 (10.3%) than in 1999-
2000 (31.7%; difference, −21.4% [95%CI, −23.6% to −19.2%];
P < .001).
Table 2 details the retrospectively collected ICU charac-
teristics for the 2 study periods. In 2015-2016, there were sig-
nificant increases in ICU admission rates per month (median,
91.0 [interquartile range {IQR}, 32.5-118.8]) vs in 1999-2000
(median, 81.0 [IQR, 40.8-185.0]; P = .02]), and the number of
ICU beds increased in 2015-2016 (median, 18.0 [IQR, 11.5-
26.5]) vs in 1999-2000 (median 18.0 [IQR, 14.0-29.0];
P = .02). Also, there were significant improvements in ICU
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mortality in 2015-2016 vs in 1999-2000 (10.7% vs 12.2%;
P < .001) and in mean (SD) ethical practice scores (in 2015-
2016, 5.6 [2.7] vs in 1999-2000, 2.9 [1.7]; P < .001). Results of
a post hoc, logistic regression analysis are presented in the
eTables 1-4 (Supplement 2).
Thedistributionofpatients, according to the typesof end-
of-life categories, is shown in the Figure and in Table 3. Over-
all in 2015-2016, there was significantly less failed CPR (6.2%
[110]) than in1999-2000(22.4%[628];difference,−16.2%[95%
CI, −18.1% to −14.3%]; P < .001), significantlymorewithhold-
ingof life-prolongingtherapies in2015-2016 (50.0%[892]) than
in 1999-2000 (40.7% [1143]; difference, 9.3% [95% CI, 6.4%
to12.3%];P < .001), andsignificantlymorewithdrawingof life-
prolonging therapies in 2015-2016 (692 [38.8%] than in 1999-
2000(695 [24.8%],difference, 14.0%[95%CI, 11.2%to16.8%];
P < .001). Active shortening of the dying process was signifi-
cantly less frequent in 2015-2016 (17 [1.0%]) than in 1999-
2000 (80 [2.9%]; difference, −1.9% [95% CI, −2.7% to −1.1%];
P < .001). Brain death was also significantly less frequent in
2015-2016 (74 [4.1%]) than in 1999-2000 (261 [9.3%]; differ-
ence, −5.2% [95% CI, −6.6% to −3.8%]; P < .001).
End-of-life categories are also presented by region in the
Figure and Table 3. In 2015-2016 vs 1999-2000, the signifi-
cant decrease in failed CPR was prominent in the south (dif-
ference, −21.3% [95%CI, −24.6% to −18.0%]; P < .001).With-
holding life-sustaining treatment exhibited a significant
increase in the south (difference, 16.8% [95% CI, 11.6% to
22.0%];P < .001),whereaswithdrawing life-sustaining treat-
ment significantly increased in all regions andwas highest in
the central region (difference, 15.7%, [95%CI, 11.3% to20.1%];
P < .001).
Among all patients admitted to the study ICUs during the
study periods, hospital mortality was significantly lower in
2015-2016 (10.7% [1458/13 625]) than in 1999-2000 (12.2%
[2701/22081]; difference, −1.5% [95% CI, −2.2% to −0.8%];
P < .001).Nopatients survived tohospitaldischargeafterbrain
Table 1. Study Population of the 22 European Centers, 1999-2000 and 2015-2016
Patient Characteristics
1999-2000
(n = 2807)a
2015-2016
(n = 1785)a Difference (95% CI)b
Age, median (IQR), yc 67 (54 to 75) 70 (59 to 79) 4.8 (3.8 to 5.8)
Age, decadesd
13-29 190 (6.8) 43 (2.4) −4.4 (−5.5 to −3.2)
30-49 377 (13.4) 166 (9.3) −4.1 (−6.0 to −2.3)
50-69 1020 (36.3) 656 (36.8) 0.4 (−2.4 to 3.3)
70-96 1220 (43.5) 920 (51.5) 8.1 (5.1 to 11.1)
Male sexd 1719 (61.3) 1079 (60.4) −0.8 (−3.7 to 2.1)
Female sexd 1085 (38.7) 706 (39.6) 0.9 (−2.0 to 3.8)
Patients by regiond
Northern Europe 587 (20.9) 424 (23.8) 2.8 (0.4 to 5.3)
Central Europe 906 (32.3) 893 (50.0) 17.8 (14.9 to 20.6)
Southern Europe 1314 (46.8) 468 (26.2) −20.6 (−23.3 to −17.8)
ICU admission (acute) diagnosesd
Respiratory 539 (19.2) 431 (24.1) 4.9 (2.5 to 7.4)
Cardiovascular 478 (17.0) 322 (18.0) 1.0 (−1.3 to 3.3)
Neurologic 472 (16.8) 277 (15.5) −1.3 (−3.5 to 0.9)
Gastrointestinal 388 (13.8) 98 (5.5) −8.3 (−10.0 to −6.7)
Surgery 348 (12.4) 339 (19.0) 6.6 (4.4 to 8.8)
Sepsis 248 (8.8) 194 (10.9) 2.0 (0.2 to 3.8)
Trauma 196 (7.0) 28 (1.6) −5.4 (−6.5 to −4.3)
Metabolic 57 (2.0) 44 (2.5) 0.4 (−0.5 to 1.3)
Miscellaneous 53 (1.9) 38 (2.1) 0.2 (−0.6 to 1.1)
Hematologic 28 (1.0) 14 (0.8) −0.2 (−0.8 to 0.3)
Chronic diseasesd
Cardiovascular 942 (33.6) 758 (42.5) 8.9 (6.0 to 11.8)
None 624 (22.2) 140 (7.8) −14.4 (−16.4 to −12.4)
Chest 313 (11.2) 180 (10.1) −1.1 (−2.9 to −0.8)
Other diseases 275 (9.8) 175 (9.8) 0.0 (−1.8 to 1.8)
Cancer 253 (9.0) 179 (10.0) 1.0 (−0.7 to 1.8)
Neurological, cognitive, musculare 135 (4.8) 141 (7.9) 3.1 (1.6 to 4.6)
Digestive 130 (4.6) 99 (5.5) 0.9 (−0.4 to 2.2)
Kidney and urinary system 71 (2.5) 64 (3.6) 1.1 (0.0 to 2.1)
Immunologic 64 (2.3) 34 (1.9) −0.4 (−1.2 to 0.5)
Missing data 0 15 (0.8) 0.8 (0.4 to 1.3)
Abbreviations: ICU, intensive care
unit; IQR, interquartile range.
a Data are reported as No (%) unless
otherwise indicated.
b For all variables except age, the
difference (95% CI) indicates
difference in percentages.
c Age was compared using the
Mann-Whitney test.
d Comparisons were determined
using a χ2 test and were not
corrected for multiplicity; these
exploratory analyses were aimed at
detecting differences between
study periods, also for the purpose
of appropriate adjustments in the
subsequent multivariable analyses
(see Supplement 2).
e Indicates 3 disease categories
counted as 1.
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death, failed CPR, or active shortening of the dying process in
either studyperiod;whereas survivalwas significantlyhigher
in 2015-2016 afterwithholding life-sustaining therapy (34.9%
[311]) than in 1999-2000 (8.9% [102]; difference, 26.0% [95%
CI, 22.5% to 29.5%]; P < .001) and after withdrawing life-
sustaining therapy (2.3% [16]) than in 1999-2000 (0.6% [4];
difference, 1.7% [95% CI, 0.4% to 3.0%]; P < .001). Mortali-
ties after specific limitations in life-prolonging therapies are
presented in Table 4.
Survival after any therapy limitation was significantly
higher in 2015-2016 (20.4% [327]) than in 1999-2000 (5.5%
[106]; difference, 14.9% [95% CI, 12.7% to 17.1%]; P < .001).
The improved 2015-2016 survival was present in all 3 regions
and higher after withholding mechanical ventilation (36.9%
[110]) than in 1999-2000 (11.5% [15]; difference, 25.5% [95%
CI, 22.9% to 28.0%]; P < .001), higher after withholding vaso-
pressors (89 [20.7%]) than in 1999-2000 (19 [4.6%]; differ-
ence, 16.1% [95% CI, 14.1% to 18.2%]; P < .001), and higher
after withholding renal replacement therapy (146 [26.9%])
than in 1999-2000 (8 [1.8%]; difference, 25.1% [95% CI,
23.0% to 27.2%]; P < .001) (Table 4).
In 2015-2016, the probability of death following the deci-
sion towithhold life-prolonging therapy (adjusted for age, sex,
diagnosis, practice, turnover, and region) was 93%within 24
hours, 98% within 48 hours, and 99% within 72 hours; fol-
lowing the decision to withdraw life-prolonging therapy, the
probability of deathwas 98%within 24hours, 99%within 48
hours, and 100%within 72 hours; and following the decision
for active shortening of the dying process, the probability of
death was 100% at all 3 time points. In 1999-2000, the prob-
ability of death following the decision to withhold life-
prolonging therapy (adjusted for age, sex, diagnosis, prac-
tice, turnover, and region) was 92% within 24 hours, 94%
within 48 hours, and 96%within 72 hours; following the de-
cision towithdraw life-prolonging therapy, the probability of
death was 99% within 24 hours, 100% within 48 hours, and
100% within 72 hours; and following the decision for active
shortening of the dying process, the probability of death was
99%within24hours, 100%within48hours, and 100%within
72 hours.
For all study patients, the median time from ICU admis-
sion until the first limitation of life-sustaining therapy was
shorter in 2015-2016 compared with 1999-2000 (2.1 vs 4.0
days;P < .001), and the ICU lengthof staywas shorter in 2015-
2016 compared with 1999-2000 (4.0 vs 5.0 days; P < .001)
(Table 5). Themedian time fromwithdrawing life-sustaining
therapy until death was shorter in 2015-2016 compared with
1999-2000(11.5vs 17.1hours;P < .02) andshorter than theme-
dian timefromwithholding life-sustaining therapyuntildeath,
whichwas longer in2015-2016comparedwith1999-2000(29.0
vs 14.1 hours; P < .001) (Table 5).
By region, themedian time from ICU admission until the
first limitationof life-sustaining therapywas 1.9days innorth-
ern Europe, 1.2 days in central Europe, and 5.0 days in south-
ern Europe in 2015-2016, comparedwith 2.6 days in northern
Europe, 3.9 days in central Europe, and 5.6 days in southern
Europe in 1999-2000 (Table 5). The median length of stay in
the ICU was 4.0 days in northern Europe, 3.0 days in central Ta
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Europe, and 6.0 days in southern Europe in 2015-2016, com-
paredwith3.0days innorthernEurope, 5.0days in central Eu-
rope, and6.0days in southernEurope in 1999-2000 (Table 5).
Discussion
In this prospective observational study of 22 European ICUs,
limitations in life-prolonging therapies occurred signifi-
cantlymore frequently, and deathwithout limitations in life-
prolonging therapies occurred significantly less frequently in
2015-2016 compared with 1999-2000.
Recentdevelopmentsmayaccount for the increase in lim-
iting life-prolonging treatment and thedecrease in failedCPR.
During the time interval between the2 studies, new laws,5,13,14
governmental statements,15-17 recommendations,6,7,18
guidelines,8,9 consensus statements by international
organizations,10,19,20 education,21 and research1,3,4,22-24 re-
garding end-of-life practices have been developed. These
frameworkshelpguide, support, andprotect physicianswhen
decisions about life-prolonging treatment are made. More-
over,donot resuscitateordershavebecomecommonplaceand
provide a formal framework for decision making and
communication.25 Public debates and social media have led
to greater awareness and openness to discuss these issues
among those in professional and lay communities.
Furthermore, palliative carehas improved inEurope7 and
worldwide. Integration of palliative care into ICUs has been
shown to result in earlier family meetings, shorter hospital
lengths of stay,26 an increase in advance directives, and a de-
crease in theuseofnonbeneficial life-prolonging treatments.27
Randomized trials demonstrated that family-support
interventions28 and communication facilitators29 reduce the
length of stay in ICUs.28,29
In recent years, physicians have gained greater knowl-
edge about ICU prognoses30 and subsequent long-term
outcomes.31 Religious,3,22,32 cultural,1 legal,32 and socioeco-
nomic factors33mayalsoplay a role. Regional differencesmay
Figure. Changes in End-of-Life Practices From 1999-2000 to 2015-2016 in 22 ICUs by European Region
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Presented are percentages of end-of-life practices in 22 centers with
randomization of center numbers. Circles indicate 1999-2000 data and squares
indicate the 2015-2016 data. The intensive care units (ICUs) have been sorted
by the 1999-2000 prevalues across all ICUs in ascending order. The same ICU
number has been kept throughout. All graphs have varying orders depending
on the sort (based from left to right on lowest to highest percentage of patients
in 1999-2000). Two centers had 17 patients with active shortening of the dying
process (data not shown).
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Table 3. Changes in End-of-life Practices From 1999-2000 to 2015-2016 in 22 Intensive Care Units
by European Region
2015-2016, % 1999-2000, % Difference (95% CI), % P Value
Overall
Failed CPR 6.2 22.4 −16.2 (−18.1 to −14.3) <.001
Withheld life-sustaining treatment 50.0 40.7 9.3 (6.4 to 12.3) <.001
Withdrew life-sustaining treatment 38.8 24.8 14.0 (11.2 to 16.8) <.001
Active shortening of the dying process 1.0 2.9 −1.9 (−2.7 to −1.1) <.001
Brain death 4.1 9.3 −5.2 (−6.6 to −3.8) <.001
Northern region
Failed CPR 4.0 13.8 −9.8 (−13.2 to −6.4) <.001
Withheld life-sustaining treatment 49.5 46.3 3.2 (−3.0 to 9.4) .34
Withdrew life-sustaining treatment 44.3 35.8 8.5 (2.4 to 14.6) <.006
Active shortening of the dying process 0.0 0.2 −0.2 (−0.6 to 0.2) >.99
Brain death 2.1 3.9 −1.8 (−3.9 to 0.3) .14
Central region
Failed CPR 7.2 20.5 −13.3 (−16.4 to −10.2) <.001
Withheld life-sustaining treatment 45.6 35.2 10.4 (5.9 to 14.9) <.001
Withdrew life-sustaining treatment 43.1 27.4 15.7 (11.3 to 20.1) <.001
Active shortening of the dying process 1.1 8.7 −7.6 (−9.6 to −5.6) <.001
Brain death 3.0 8.2 −5.2 (−7.3 to −3.1) <.001
Southern region
Failed CPR 6.2 27.5 −21.3 (−24.6 to −18.0) <.001
Withheld life-sustaining treatment 58.8 42.0 16.8 (11.6 to 22.0) <.001
Withdrew life-sustaining treatment 25.4 18.0 7.4 (2.9 to 11.9) <.001
Active shortening of the dying process 1.5 0.0 1.5 (0.4 to 2.6) <.001
Brain death 8.1 12.5 −4.4 (−7.5 to −1.3) .01
Central vs Northern Region 1999-2000a
Failed CPR 20.5 13.8 −6.7 (−10.5 to −2.9) .001
Withheld life-sustaining treatment 35.2 46.3 11.1 (6.0 to 16.2) <.001
Withdrew life-sustaining treatment 27.4 35.8 8.4 (3.6 to 13.2) .001
Active shortening of the dying process 8.7 0.2 −8.5 (−10.4 to −6.6) <.001
Brain death 8.2 3.9 −4.3 (−6.7 to −1.9) .001
Southern vs Northern Region 1999-2000a
Failed CPR 27.5 13.8 −13.7 (−17.4 to −10.0) <.001
Withheld life-sustaining treatment 42.0 46.3 4.3 (−0.5 to 9.1) .08
Withdrew life-sustaining treatment 18.0 35.8 17.8 (13.4 to 22.2) <.001
Active shortening of the dying process 0.0 0.2 0.2 (−0.2 to 0.6) .31
Brain death 12.5 3.9 −8.6 (−11.0 to −6.2) <.001
Southern vs Central Region 1999-2000a
Failed CPR 27.5 20.5 −7.0 (−10.6 to −3.4) <.001
Withheld life-sustaining treatment 42.0 35.2 −6.8 (−10.9 to −2.7) .001
Withdrew life-sustaining treatment 18.0 27.4 9.4 (5.8 to 13.0) <.001
Active shortening of the dying process 0.0 8.7 8.7 (6.9 to 10.5) <.001
Brain death 12.5 8.2 −4.3 (−6.8 to −1.8) .001
Central vs Northern Region 2015-2016a
Failed CPR 7.2 4.0 −3.2 (−5.7 to −0.7) .03
Withheld life-sustaining treatment 45.6 49.5 3.9 (−1.9 to 9.7) .19
Withdrew life-sustaining treatment 43.1 44.3 1.2 (−4.5 to 6.9) .68
Active shortening of the dying process 1.1 0.0 −1.1 (−1.8 to −0.4) .04
Brain death 3.0 2.1 −0.9 (−2.7 to 0.9) .45
(continued)
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bedecreasingdue to increasing secularism inpartsofEurope34
andgreater international consensus for end-of-life practices.1
Many of the centers included in this study reported nu-
merical or statistically significant increases in country end-
of-life legislationandguidelines, ICUwrittenend-of-lifeguide-
lines,protocolsandtriggers for limitations,communicationand
bioethics courses, end-of-life discussions and deliberations
about levels of care, palliative care and ethics consultations,
and family meetings since 1999-2000. These changes re-
sulted in significant, overall improvements in theethical prac-
tice score. Other factors associated with treatment limitation
included physician religion,3,22 patient age, and chronic dis-
ease. The latter 2 factors were previously shown to contrib-
ute to decisions to withhold ICU support.35
An important finding of this study was the higher sur-
vival rates after limitations in life-prolonging therapies. Limi-
tations occur not only at the end-of-life but also earlier to
respect patient wishes and to avoid invasive therapies likely
to prolong the dying process or result in poor quality of life.
Death occurredmore often after the actual withdrawal of life-
sustaining treatments than after withholding potential future
or present life-prolonging therapies. In 2015-2016, more
patients survived after withholding mechanical ventilation,
vasopressor use, and renal replacement therapy, which may
reflect improved ICU practices with more patients surviving
acute illnesses.
Previous end-of-life practice comparison studies show
contradictory results. Between 1987 and 1993 Prendergast
Table 4. Outcome of PatientsWith andWithout Limitations of Life-Sustaining Treatments and First Limitations
(Withholding orWithdrawing of Life-Sustaining Treatments) for CPR, Endotracheal Tube, Mechanical
Ventilation, Vasopressor, and Renal Replacement Therapy in 22 European Centers, 1999-2000 vs 2015-2016
Characteristics
No. of Patients Who Died/Total No. (%)
Difference (95% CI),% P Valuea
1999-2000
(n = 2807)
2015-2016
(n = 1785)
Died without limitation of therapyb 889/889 (100.0) 184/184 (100.0)
Died with limitation of therapy 1812/1918
(94.5)
1274/1601 (79.6) −14.9 (−17.0 to −12.8) <.001
First limitation in patients with
withholding of life-sustaining
treatmentc
CPR 1635/1736
(94.2)
1151/1469 (78.4) −15.8 (−17.9 to −13.7) <.001
Endotracheal tube 120/168 (71.4) 205/349 (58.7) −12.7 (−15.5 to −9.9) .006
Mechanical ventilation 116/131 (88.5) 188/298 (63.1) −25.5 (−28.0 to −22.9) <.001
Vasopressor 393/412 (95.4) 340/429 (79.3) −16.1 (−18.2 to −14.1) <.001
Renal replacement therapy 432/440 (98.2) 397/543 (73.1) −25.1 (−27.2 to −23.0) <.001
First limitation in patients with
withdrawing of life-sustaining
treatmentc
CPR 45/46 (97.8) 18/18 (100.0) 2.2 (1.6 to 2.7) >.99
Endotracheal tube 30/30 (100) 130/137 (94.9) −5.1 (−6.1 to −4.1) .35
Mechanical ventilation 73/74 (98.6) 188/196 (95.9) −2.7 (−3.7 to −1.7) .45
Vasopressor 232/232 (100.0) 259/263 (98.5) −1.5 (−2.1 to −1.0) .13
Renal replacement therapy 97/97 (100.0) 81/81 (100.0)
Abbreviation: CPR, cardiopulmonary
resuscitation.
a P values were determined using a χ2
or Fisher exact test.
b The Table presents study patients
who lived or died with or without
limitations. There were no patients
who survived in the failed CPR or
brain death categories (without
limitations of therapies.)
c The first limitation could, and not
infrequently did, involve
withholding or withdrawingmore
than one life-sustaining treatment.
Thus, the sum of the total of the
first limitations may exceed the
number of patients in whom
life-sustaining treatment was
withheld or withdrawn.
Table 3. Changes in End-of-life Practices From 1999-2000 to 2015-2016 in 22 Intensive Care Units
by European Region (continued)
2015-2016, % 1999-2000, % Difference (95% CI), % P Value
Southern vs Northern Region 2015-2016a
Failed CPR 6.2 4.0 −2.2 (−5.1 to 0.7) .17
Withheld life-sustaining treatment 58.8 49.5 −9.3 (−15.8 to −2.8) .006
Withdrew life-sustaining treatment 25.4 44.3 18.9 (12.7 to 25.1) <.001
Active shortening of the dying process 1.5 0.0 −1.5 (−2.6 to −0.4) .02
Brain death 8.1 2.1 −6.0 (−8.8 to −3.2) <.001
Southern vs Central Region 2015-2016a
Failed CPR 6.2 7.2 1.0 (−1.8 to 3.8) .57
Withheld life-sustaining treatment 58.8 45.6 −13.2 (−18.7 to −7.7) <.001
Withdrew life-sustaining treatment 25.4 43.1 17.7 (12.6 to 22.8) <.001
Active shortening of the dying process 1.5 1.1 −0.4 (−1.7 to 0.9) .61
Brain death 8.1 3.0 −5.1 (−7.8 to −2.4) <.001
Abbreviation: CPR, cardiopulmonary
resuscitation.
a Column 2 displays the percentage
value for the first-mentioned region,
and column 3 displays the value for
the second-mentioned region.
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Table 5. Time Frames for Length of Stay to First Limitation, to Death After First Limitation, and forWithholding andWithdrawing
of Life-Sustaining Therapy in PatientsWith End-of-Life Decisions, by Region and by Type of Limitation in 22 European Centers,
1999-2000 (n = 2807) and 2015-2016 (n = 1785)
Years of Cohort
Median (IQR)
Difference (95% CI)a P Valueb1999-2000 2015-2016
Overall
Length of stay in the ICU, d 5.0 (1.0 to 13.0) 4.0 (1.0 to 11.0) −1.8 (−2.8 to −0.9) <.001
No. of patients 2799c 1785
Time from ICU admission to first limitation, d 4.0 (1.0 to12.3) 2.1 (0.3 to 7.5) −3.5 (−4.5 to −2.5) <.001
No. of patients 1891 1538
Time from first limitation of treatment until death, h 16.2 (3.6 to 57.0) 20.0 (3.0 to 87.9) −32.4 (−50.2 to 14.7) .08
No. of patients 1817 1274
Time from withholding life-sustaining therapy
until death, h
14.1 (2.8 to 63.5) 29.0 (4.5 to 134.8) 54.2 (24.3 to 84.2) <.001
No. of patients 1034 581
Time from withdrawing life-sustaining therapy
until death, h
17.1 (4.5 to 49.8) 11.5 (2.3 to 54.6) 26.7 (7.5 to 45.9) .02
No. of patients 686 676
Northern region
Length of stay in the ICU, d 3.0 (1.0 to 11.0) 4.0 (1.0 to 10.0) −0.99 (−2.64 to 0.66) .68
No. of patients 586 424
Time from ICU admission to first limitation, d 2.6 (0.6 to 9.9) 1.9 (0.4 to 6.9) −2.3 (−3.9 to −0.7) <.01
No. of patients 474 376
Time from first limitation of treatment until death, h 12.7 (3.6 to 41.5) 20.9 (3.5 to 69.7) −56.3 (−87.5 to −25.1) .04
No. of patients 471 335
Time from withholding life-sustaining therapy
until death, h
9.6 (3.0 to 41.2) 35.0 (5.1 to 147.4) 79.9 (39.3 to 120.5) <.001
No. of patients 260 147
Time from withdrawing life-sustaining therapy
until death, h
15.0 (4.6 to 43.0) 13.0 (3.3 to 30.9) 39.3 (−9.1 to 87.8) .22
No. of patients 206 188
Central region
Length of stay in the ICU, d 5.0 (2.0 to 15.0) 3.0 (1.0 to 9.0) −4.5 (−6.1 to 3.0) <.001
No. of patients 903 893
Time from ICU admission to first limitation, d 3.9 (0.8 to 14.0) 1.2 (0.1 to 5.1) 6.8 (−8.4 to −5.2) <.001
No. of patients 640 763
Time from first limitation of treatment until death, h 26.6 (5.8 to 92.6) 23.5 (2.7 to 115.4) −17.4 (−52.6 to 17.9) .13
No. of patients 578 569
Time from withholding life-sustaining therapy
until death, h
32.7 (6.3 to 160.9) 57.0 (8.6 to 286.5) 39.7 (−42.8 to 122.2) .11
No. of patients 243 187
Time from withdrawing life-sustaining therapy
until death, h
15.6 (5.0 to 51.6) 12.9 (1.9 to 75.7) 32.1 (4.7 to 59.6) .12
No. of patients 246 372
Southern region
Length of stay in the ICU, d 6.0 (2.0 to 14.0) 6.0 (2.0 to 18.0) 1.9 (0.1 to 3.7) .10
No. of patients 1310 468
Time from ICU admission to first limitation, d 5.6 (1.5 to 12.7) 5.0 (1.3 to 15.9) 1.0 (−0.9 to 2.8) .84
No. of patients 777 399
Time from first limitation of treatment until death, h 12.5 (2.0 to 50.5) 16.2 (3.0 to 62.1) −11.7 (−35.6 to 12.1) .14
No. of patients 768 370
Time from withholding life-sustaining therapy
until death, h
11.0 (1.5 to 54.5) 18.5 (3.4 to 74.2) 23.9 (−9.8 to 57.6) .01
No. of patients 531 247
Time from withdrawing life-sustaining therapy
until death, h
20.8 (4.0 to 50.1) 10.3 (2.5 to 32.7) −11.2 (−31.9 to 9.6) .12
No. of patients 234 116
a Difference (95% CI) indicates difference of means, 2015-2016minus
1999-2000 values.
bP values were determined byMann-Whitney test.
c Cell reports 2799 patients instead of 2807 because there were 8 patients with
missing data.
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and Luce demonstrated a 39% decrease in failed CPR and a
39% increase in withdrawing and withholding treatments in
2 US ICUs.36 McLean et al compared the mode of dying
between 1988 and 1993 in 2 Canadian ICUs and found 23%
and 34% increases in the withdrawal of life-sustaining treat-
ments in the 2 ICUs.37 Jakobson et al found no significant
differences in CPR or withholding of life-prolonging thera-
pies in an Israeli ICU between 1994 and 1999.38 The authors
suggested that the lack of change was due to the already low
CPR rate and high withholding rate. In a French single-
center study by Lesieur et al, limitations increased by 16%
from 2012 to 2016, while failed CPR decreased 36%.39 The
present study found an increase from 1999 to 2016 of with-
holding (9%) and withdrawing (14%) life-sustaining thera-
pies, whereas failed CPR decreased (-16%).
Thepresent studydemonstrated that active shorteningof
the dying process is uncommon in the ICU. Despite increas-
ingpublicapproval,morecountriespermittingeuthanasia, and
euthanasia increasing as the cause of death in the Nether-
lands and Belgium,11,40 there was a slight decrease in active
shortening of the dying process in the study. This may be re-
lated tophysician reluctance toactively shorten thedyingpro-
cessbecause ICUpatients cannotexpress theirwishesandpro-
vide an explicit request, making this action illegal even in
Belgium and theNetherlandswhere euthanasia is permitted.
Euthanasia and active shortening of thedyingprocess are not
needed in the ICUbecauseoncecaregivers andsurrogates con-
clude that ongoing interventions are not in the patient’s best
interest, death typically ensues rather quickly afterwithdraw-
ing life-prolonging treatment.
Although some changes were statistically significant be-
cause of the large numbers of patients, they were not clini-
cally relevant, such as thedecrease in active shortening of the
dyingprocessand ICU lengthof stay.Despite the fact thatmore
ICUs in thesouthernregionadmittedpatients, therewere fewer
patients admitted in the southern region in 2015-2016 than in
1999-2000 compared with the northern and central regions.
Thiswasmost likely related to themuch lower number of ICU
beds andmonthly admissions to ICUs in the southern region
compared with ICUs in the northern and central regions.
Strengthsof the study include itsmultinationalnature, the
large number of patients, use of the same centers and defini-
tions, the samephysiciansbeing responsible for end-of-lifede-
cisions and data collection, methods to improve quality, the
long time interval between studies, and the evaluation of
changes in the study ICUs (especially ethical practices) in re-
lation to end-of-life outcomes.
Limitations
This study has several limitations. First, this follow-up study
includes only 59% of previous centers, different percentages
of patients from the regions, and different physicians treat-
ingmanyof thepatients. Second, themajorityof the ICUswere
academically affiliated and may not be representative of Eu-
ropeanICUsmoregenerally.Third,while secular trends, chang-
ingethical views, andpublic awarenessmaybe responsible for
many of the changes observed, the study design did not al-
low for direct assessment of how ethical principles and laws
affect outcomes. Fourth, the data used to calculate the ethi-
cal practice score were collected retrospectively and may be
subject to recall bias and social desirability bias. Fifth, it re-
mains possible that changes in admission case mix not ad-
justed for in the analyses, or substantial changes in survival
rates related to changes in organizational factors and quality
of care, may be confounders responsible for some of the ob-
servedchanges. Sixth, thenumberofpatientsnot receiving in-
dicated treatment limitations could not be determined.
Conclusions
Among patients who had treatment limitations or died in 22
European ICUs in 2015-2016, compared with data previously
reported from the same ICUs in 1999-2000, limitations in life-
prolonging therapies occurred significantly more frequently
anddeathwithout limitations in life-prolonging therapies oc-
curred significantly less frequently. Although these findings
suggest a shift in end-of-life practices in European ICUs, the
study is limited in that patients who survived ICU hospital-
ization without treatment limitations were not included.
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